RNS Number : 5994T Renalytix PLC 21 March 2023     Renalytix plc    ("Renalytix" or the "Company")   Update on FDA De Novo Marketing Authorization Process   LONDON and SALT LAKE CITY , March 21, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the review process with the Food and

RNS Number : 6575S Renalytix PLC 13 March 2023   Renalytix plc    ("Renalytix" or the "Company")   Statement re. Silicon Valley Bank   LONDON and SALT LAKE CITY , March 13, 2023   --  Renalytix plc   (NASDAQ: RNLX) (LSE: RENX) is aware of media reports indicating the closure of Silicon Valley Bank

RNS Number : 0458S Renalytix PLC 07 March 2023     Issue of Shares   LONDON and SALT LAKE CITY , March 7, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 166,674 new ordinary shares of £0.0025 each in the capital of the

RNS Number : 6255P Renalytix PLC 10 February 2023     TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)   i 1a. Identity of the issuer or the underlying issuer of

RNS Number : 6203P Renalytix PLC 10 February 2023   Renalytix plc    ("Renalytix" or the "Company")   Director/PDMR Dealing   LONDON and SALT LAKE CITY , February 10, 2023   --  Renalytix plc   (NASDAQ: RNLX) (LSE: RENX) confirms that further to the announcement on February 8 of a c.

RNS Number : 3776P Renalytix PLC 09 February 2023     Renalytix to Participate in the BTIG MedTech, Digital Health , Life Science & Diagnostic Tools Conference   LONDON and SALT LAKE CITY , February 9, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will be

RNS Number : 2418P Renalytix PLC 08 February 2023   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES

RNS Number : 8999N Renalytix PLC 26 January 2023   Renalytix plc (" Renalytix " or the " Company ")     Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States   Award for consortium of industry,

RNS Number : 1089M Renalytix PLC 09 January 2023   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this

RNS Number : 1075M Renalytix PLC 09 January 2023   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders